Galcanezumab

A new direct-to-consumer health care program launched by Eli Lilly has the potential to improve access to diabetes, obesity and migraine medications in the United States.

Women with menstrual migraine who were treated with galcanezumab had fewer monthly migraine headache days compared with women who received placebo, according to an analysis of three phase 3 trials.